@Starlink please read the study overview below and then re-read the final results announcement. The primary endpoint of the trail was not achieved, therefore the trial FAILED....
Please stop spreading false truths that this trial did not fail to meet it's intended end points.
Results in the trial did show some benefits it certain age cohorts so it was not all negative. But the FACT remains that the primary endpoint WAS NOT REACHEDStudy Overview
The randomised, double-blinded, placebo-controlled clinical study of VIRALEZE™ assesses SARS-CoV-2 viral load in the nasal cavity of patients with COVID-19 while using VIRALEZE™. The primary endpoint of the clinical study is the level of a patient’s viral load over a seven-day treatment period.
- Forums
- ASX - By Stock
- SPL
- Covid is not over by a long shot
Covid is not over by a long shot, page-73
-
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.1¢ |
Change
-0.001(0.55%) |
Mkt cap ! $37.52M |
Open | High | Low | Value | Volume |
9.0¢ | 9.1¢ | 9.0¢ | $47.58K | 525.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49413 | 9.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.2¢ | 22000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49413 | 0.091 |
1 | 2750 | 0.090 |
2 | 97420 | 0.089 |
1 | 5000 | 0.088 |
1 | 73255 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.092 | 22000 | 1 |
0.093 | 30790 | 3 |
0.094 | 106393 | 1 |
0.099 | 1285 | 1 |
0.100 | 112106 | 4 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
SPL (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online